FY23 task order H - 126361 wedgewood suite M & N expansion MOD 001

Ended Awarded Last action

Contract number
75N91023F00015
Awardee
Awarding agency
Obligated
-$136,805

Award facts

Opportunity
  • NCIOSFM230131 Solicitation number
Contract value 0% obligated
$16,398,667.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21701, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00006 -$136,805
Other Administrative Action P00005 $0
Terminate for Convenience P00004 · EOI:: implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI $0
Supplemental Agreement for work within scope P00003 $0
Change Order P00002 $888,749
Other Administrative Action P00001 $0
Original award FY23 task order H - 126361 wedgewood suite M & N expansion $15,646,723

About this award

This delivery order task (H-126361) was awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., by the National Cancer Institute on September 27, 2023, for the Wedgewood Suite M & N Expansion modification project in Frederick, Maryland. The contract carries a ceiling value of $16.4 million and extends through June 18, 2026, utilizing a cost-plus-fixed-fee pricing structure with no set-aside designation. Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center contractor primarily serving the National Cancer Institute and National Institutes of Health, providing comprehensive biomedical research and facilities support services including medical research, clinical trials, facility management, and advanced technological solutions. This task order represents one of numerous cost-plus-fixed-fee delivery orders the company has secured for diverse projects spanning cancer research, vaccine development, clinical trials, and facilities infrastructure improvements.

The Wedgewood facility expansion modification aligns with the National Cancer Institute's infrastructure and facilities management objectives, supporting the ongoing operations at the Frederick National Laboratory for Cancer Research. As a subsidiary of Leidos Holdings, Inc.—a major federal contractor with multi-billion-dollar contract portfolios across defense, intelligence, health, and civilian sectors—Leidos Biomedical Research Inc. brings substantial organizational support and resources to this contract. The task order is issued under a broader delivery order vehicle framework that enables flexible procurement for mission-critical research and operational support without requiring individual full-and-open competitions for discrete projects, allowing the National Cancer Institute to efficiently execute infrastructure and facilities work supporting its research mission.

Quick answers

Who was awarded contract 75N91023F00015?

75N91023F00015 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 27, 2023.

How much is contract 75N91023F00015 worth?

The government has obligated -$136,805 on 75N91023F00015. Its current value, with exercised options, is $16,398,667.

Is contract 75N91023F00015 an order under another contract?

Yes. 75N91023F00015 is a delivery order under 75N91019D00024, an indefinite delivery contract.

Was contract 75N91023F00015 competed?

The extent of competition for 75N91023F00015 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award